Cargando…
Immune phenotypes predict survival in patients with glioblastoma multiforme
BACKGROUND: Glioblastoma multiforme (GBM), a common primary malignant brain tumor, rarely disseminates beyond the central nervous system and has a very bad prognosis. The current study aimed at the analysis of immunological control in individual patients with GBM. METHODS: Immune phenotypes and plas...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009501/ https://www.ncbi.nlm.nih.gov/pubmed/27585656 http://dx.doi.org/10.1186/s13045-016-0272-3 |
_version_ | 1782451524616585216 |
---|---|
author | Mostafa, Haouraa Pala, Andrej Högel, Josef Hlavac, Michal Dietrich, Elvira Westhoff, M. Andrew Nonnenmacher, Lisa Burster, Timo Georgieff, Michael Wirtz, C. Rainer Schneider, E. Marion |
author_facet | Mostafa, Haouraa Pala, Andrej Högel, Josef Hlavac, Michal Dietrich, Elvira Westhoff, M. Andrew Nonnenmacher, Lisa Burster, Timo Georgieff, Michael Wirtz, C. Rainer Schneider, E. Marion |
author_sort | Mostafa, Haouraa |
collection | PubMed |
description | BACKGROUND: Glioblastoma multiforme (GBM), a common primary malignant brain tumor, rarely disseminates beyond the central nervous system and has a very bad prognosis. The current study aimed at the analysis of immunological control in individual patients with GBM. METHODS: Immune phenotypes and plasma biomarkers of GBM patients were determined at the time of diagnosis using flow cytometry and ELISA, respectively. RESULTS: Using descriptive statistics, we found that immune anomalies were distinct in individual patients. Defined marker profiles proved highly relevant for survival. A remarkable relation between activated NK cells and improved survival in GBM patients was in contrast to increased CD39 and IL-10 in patients with a detrimental course and very short survival. Recursive partitioning analysis (RPA) and Cox proportional hazards models substantiated the relevance of absolute numbers of CD8 cells and low numbers of CD39 cells for better survival. CONCLUSIONS: Defined alterations of the immune system may guide the course of disease in patients with GBM and may be prognostically valuable for longitudinal studies or can be applied for immune intervention. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0272-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5009501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-50095012016-09-03 Immune phenotypes predict survival in patients with glioblastoma multiforme Mostafa, Haouraa Pala, Andrej Högel, Josef Hlavac, Michal Dietrich, Elvira Westhoff, M. Andrew Nonnenmacher, Lisa Burster, Timo Georgieff, Michael Wirtz, C. Rainer Schneider, E. Marion J Hematol Oncol Research BACKGROUND: Glioblastoma multiforme (GBM), a common primary malignant brain tumor, rarely disseminates beyond the central nervous system and has a very bad prognosis. The current study aimed at the analysis of immunological control in individual patients with GBM. METHODS: Immune phenotypes and plasma biomarkers of GBM patients were determined at the time of diagnosis using flow cytometry and ELISA, respectively. RESULTS: Using descriptive statistics, we found that immune anomalies were distinct in individual patients. Defined marker profiles proved highly relevant for survival. A remarkable relation between activated NK cells and improved survival in GBM patients was in contrast to increased CD39 and IL-10 in patients with a detrimental course and very short survival. Recursive partitioning analysis (RPA) and Cox proportional hazards models substantiated the relevance of absolute numbers of CD8 cells and low numbers of CD39 cells for better survival. CONCLUSIONS: Defined alterations of the immune system may guide the course of disease in patients with GBM and may be prognostically valuable for longitudinal studies or can be applied for immune intervention. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0272-3) contains supplementary material, which is available to authorized users. BioMed Central 2016-09-01 /pmc/articles/PMC5009501/ /pubmed/27585656 http://dx.doi.org/10.1186/s13045-016-0272-3 Text en © Mostafa et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Mostafa, Haouraa Pala, Andrej Högel, Josef Hlavac, Michal Dietrich, Elvira Westhoff, M. Andrew Nonnenmacher, Lisa Burster, Timo Georgieff, Michael Wirtz, C. Rainer Schneider, E. Marion Immune phenotypes predict survival in patients with glioblastoma multiforme |
title | Immune phenotypes predict survival in patients with glioblastoma multiforme |
title_full | Immune phenotypes predict survival in patients with glioblastoma multiforme |
title_fullStr | Immune phenotypes predict survival in patients with glioblastoma multiforme |
title_full_unstemmed | Immune phenotypes predict survival in patients with glioblastoma multiforme |
title_short | Immune phenotypes predict survival in patients with glioblastoma multiforme |
title_sort | immune phenotypes predict survival in patients with glioblastoma multiforme |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009501/ https://www.ncbi.nlm.nih.gov/pubmed/27585656 http://dx.doi.org/10.1186/s13045-016-0272-3 |
work_keys_str_mv | AT mostafahaouraa immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme AT palaandrej immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme AT hogeljosef immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme AT hlavacmichal immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme AT dietrichelvira immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme AT westhoffmandrew immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme AT nonnenmacherlisa immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme AT burstertimo immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme AT georgieffmichael immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme AT wirtzcrainer immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme AT schneideremarion immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme |